Skip to main content
S&P 5007,805.45-0.08%DOW51,863.95+0.40%NASDAQ27,256.46-0.40%BTC$82,401.00-1.78%ETH$2,505.74-1.48%GOLD$4,193.20-0.55%OIL$93.77+2.09%
Smart Investors Daily
SID Premium
AL

NASDAQ · ALVOW

Alvotech

Healthcare · Drug Manufacturers - Specialty & Generic

$0.45

Down-$0.18 (-40.15%)

Updated Oct 12, 2026, 5:51 PM

SID Score

6.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
170.79M
P/E ratio
17.23
Dividend yield
0.00%
52-week range
$0.12 – $0.78
Volume
1.5K
Avg. volume
6.07K

Price performance · ALVOW

ALVOW price history

1M range · 0 trading sessions · Daily adjusted prices

ALVOW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ALVOW news

The latest Smart Investors Daily articles mentioning ALVOW.

Stock researchCompany · Overview

ALVOW research

Overview

Company profile and research snapshot.

Company profile

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 6, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech and LOTTE Biologics signing ceremony Alvotech and LOTTE Biologics signing ceremony to commemorate the formation of a strategic manufacturing agreement on October 6, 2026 Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (

Yahoo · Oct 5, 2026

Alvotech stock surges after FDA manufacturing approval

Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second production suite at its Reykjavik facility.

Yahoo · Oct 5, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the Reykjavik site REYKJAVIK, Iceland (October 5, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has ap

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By